Supplementation with EPA or fish oil for 11 months lowers circulating lipids, but does not delay the onset of diabetes in UC Davis-type 2 diabetes mellitus rats

Bethany P. Cummings, Kimber Stanhope, James L. Graham, Steven C. Griffen, Peter J Havel

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

EPA or fish oil supplementation has been suggested as treatments for the prevention of type 2 diabetes mellitus (T2DM) due to their lipid-lowering and potential insulin-sensitising effects. We investigated the effects of supplementation with EPA (1g/kg body weight per d) or fish oil (3g/kg body weight per d) on the age of onset of T2DM and circulating glucose, insulin, lipids, leptin and adiponectin in UC Davis (UCD)-T2DM rats. Animals were divided into three groups starting at 1month of age: control, EPA and fish oil. All the animals were followed until diabetes onset or for up to 12 months of age. Monthly fasting blood samples were collected for the measurement of glucose, lipids, hormones and C-reactive protein (CRP). Neither EPA nor fish oil delayed the onset of T2DM or altered fasting plasma glucose, insulin, CRP, adiponectin or leptin concentrations. The groups did not differ in energy intake or body weight. Fish oil treatment lowered fasting plasma TAG concentrations by 39 (sd 7)% (P<0001) and EPA lowered fasting plasma NEFA concentrations by 23 (sd 5)% (P<005) at 4 months of age compared with the control group. EPA and fish oil lowered fasting plasma cholesterol concentrations at 4 months of age by 19 (sd 4) and 22 (sd 4)% compared with the control group, respectively (both P<001). In conclusion, EPA and fish oil supplementation lowers circulating lipid concentrations, but does not delay the onset of T2DM in UCD-T2DM rats.

Original languageEnglish (US)
Pages (from-to)1628-1634
Number of pages7
JournalBritish Journal of Nutrition
Volume104
Issue number11
DOIs
StatePublished - Dec 14 2010

Fingerprint

Fish Oils
Type 2 Diabetes Mellitus
Lipids
Fasting
Adiponectin
Body Weight
Insulin
Leptin
Glucose
C-Reactive Protein
Control Groups
Energy Intake
Age of Onset
Nonesterified Fatty Acids
Cholesterol
Hormones

Keywords

  • Diabetes prevention
  • EPA
  • Fish oil
  • TAG

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Supplementation with EPA or fish oil for 11 months lowers circulating lipids, but does not delay the onset of diabetes in UC Davis-type 2 diabetes mellitus rats. / Cummings, Bethany P.; Stanhope, Kimber; Graham, James L.; Griffen, Steven C.; Havel, Peter J.

In: British Journal of Nutrition, Vol. 104, No. 11, 14.12.2010, p. 1628-1634.

Research output: Contribution to journalArticle

@article{0bf94f1d422a48c7b2b9511f823cf7b8,
title = "Supplementation with EPA or fish oil for 11 months lowers circulating lipids, but does not delay the onset of diabetes in UC Davis-type 2 diabetes mellitus rats",
abstract = "EPA or fish oil supplementation has been suggested as treatments for the prevention of type 2 diabetes mellitus (T2DM) due to their lipid-lowering and potential insulin-sensitising effects. We investigated the effects of supplementation with EPA (1g/kg body weight per d) or fish oil (3g/kg body weight per d) on the age of onset of T2DM and circulating glucose, insulin, lipids, leptin and adiponectin in UC Davis (UCD)-T2DM rats. Animals were divided into three groups starting at 1month of age: control, EPA and fish oil. All the animals were followed until diabetes onset or for up to 12 months of age. Monthly fasting blood samples were collected for the measurement of glucose, lipids, hormones and C-reactive protein (CRP). Neither EPA nor fish oil delayed the onset of T2DM or altered fasting plasma glucose, insulin, CRP, adiponectin or leptin concentrations. The groups did not differ in energy intake or body weight. Fish oil treatment lowered fasting plasma TAG concentrations by 39 (sd 7){\%} (P<0001) and EPA lowered fasting plasma NEFA concentrations by 23 (sd 5){\%} (P<005) at 4 months of age compared with the control group. EPA and fish oil lowered fasting plasma cholesterol concentrations at 4 months of age by 19 (sd 4) and 22 (sd 4){\%} compared with the control group, respectively (both P<001). In conclusion, EPA and fish oil supplementation lowers circulating lipid concentrations, but does not delay the onset of T2DM in UCD-T2DM rats.",
keywords = "Diabetes prevention, EPA, Fish oil, TAG",
author = "Cummings, {Bethany P.} and Kimber Stanhope and Graham, {James L.} and Griffen, {Steven C.} and Havel, {Peter J}",
year = "2010",
month = "12",
day = "14",
doi = "10.1017/S0007114510002655",
language = "English (US)",
volume = "104",
pages = "1628--1634",
journal = "British Journal of Nutrition",
issn = "0007-1145",
publisher = "Cambridge University Press",
number = "11",

}

TY - JOUR

T1 - Supplementation with EPA or fish oil for 11 months lowers circulating lipids, but does not delay the onset of diabetes in UC Davis-type 2 diabetes mellitus rats

AU - Cummings, Bethany P.

AU - Stanhope, Kimber

AU - Graham, James L.

AU - Griffen, Steven C.

AU - Havel, Peter J

PY - 2010/12/14

Y1 - 2010/12/14

N2 - EPA or fish oil supplementation has been suggested as treatments for the prevention of type 2 diabetes mellitus (T2DM) due to their lipid-lowering and potential insulin-sensitising effects. We investigated the effects of supplementation with EPA (1g/kg body weight per d) or fish oil (3g/kg body weight per d) on the age of onset of T2DM and circulating glucose, insulin, lipids, leptin and adiponectin in UC Davis (UCD)-T2DM rats. Animals were divided into three groups starting at 1month of age: control, EPA and fish oil. All the animals were followed until diabetes onset or for up to 12 months of age. Monthly fasting blood samples were collected for the measurement of glucose, lipids, hormones and C-reactive protein (CRP). Neither EPA nor fish oil delayed the onset of T2DM or altered fasting plasma glucose, insulin, CRP, adiponectin or leptin concentrations. The groups did not differ in energy intake or body weight. Fish oil treatment lowered fasting plasma TAG concentrations by 39 (sd 7)% (P<0001) and EPA lowered fasting plasma NEFA concentrations by 23 (sd 5)% (P<005) at 4 months of age compared with the control group. EPA and fish oil lowered fasting plasma cholesterol concentrations at 4 months of age by 19 (sd 4) and 22 (sd 4)% compared with the control group, respectively (both P<001). In conclusion, EPA and fish oil supplementation lowers circulating lipid concentrations, but does not delay the onset of T2DM in UCD-T2DM rats.

AB - EPA or fish oil supplementation has been suggested as treatments for the prevention of type 2 diabetes mellitus (T2DM) due to their lipid-lowering and potential insulin-sensitising effects. We investigated the effects of supplementation with EPA (1g/kg body weight per d) or fish oil (3g/kg body weight per d) on the age of onset of T2DM and circulating glucose, insulin, lipids, leptin and adiponectin in UC Davis (UCD)-T2DM rats. Animals were divided into three groups starting at 1month of age: control, EPA and fish oil. All the animals were followed until diabetes onset or for up to 12 months of age. Monthly fasting blood samples were collected for the measurement of glucose, lipids, hormones and C-reactive protein (CRP). Neither EPA nor fish oil delayed the onset of T2DM or altered fasting plasma glucose, insulin, CRP, adiponectin or leptin concentrations. The groups did not differ in energy intake or body weight. Fish oil treatment lowered fasting plasma TAG concentrations by 39 (sd 7)% (P<0001) and EPA lowered fasting plasma NEFA concentrations by 23 (sd 5)% (P<005) at 4 months of age compared with the control group. EPA and fish oil lowered fasting plasma cholesterol concentrations at 4 months of age by 19 (sd 4) and 22 (sd 4)% compared with the control group, respectively (both P<001). In conclusion, EPA and fish oil supplementation lowers circulating lipid concentrations, but does not delay the onset of T2DM in UCD-T2DM rats.

KW - Diabetes prevention

KW - EPA

KW - Fish oil

KW - TAG

UR - http://www.scopus.com/inward/record.url?scp=78650027196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650027196&partnerID=8YFLogxK

U2 - 10.1017/S0007114510002655

DO - 10.1017/S0007114510002655

M3 - Article

C2 - 20735878

AN - SCOPUS:78650027196

VL - 104

SP - 1628

EP - 1634

JO - British Journal of Nutrition

JF - British Journal of Nutrition

SN - 0007-1145

IS - 11

ER -